BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xarelto rivaroxaban: Additional Phase III data

Additional data from the double-blind, international Phase III ATLAS ACS 2-TIMI 51 trial in 15,526 patients showed that twice-daily 2.5 and 5 mg rivaroxaban plus standard of care (SOC) for a mean of 13 months significantly reduced a composite of CV death, MI and stroke, the primary endpoint, vs. placebo plus SOC (9.1% and 8.8%, respectively, vs. 10.7%, p=0.02 and p=0.03). Low-dose rivaroxaban plus SOC also significantly reduced the rate of CV death (2.7% vs. 4.1%, p=0.002) and death from any cause vs. placebo plus SOC (2.9% vs....

Read the full 420 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >